Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07754500

Deep Optical Imaging of Tissue (DOIT)

In medical imaging, X-ray-based methods are widely used, which means that patients are exposed to ionizing radiation. In addition, invasive tissue samples often need to be taken with biopsy needles to, for example, safely determine or rule out a cancer diagnosis. With this project, the investigators evaluate a light-based (optical) method combined with ultrasound that is completely harmless to humans, ultrasound-optical-tomography (UOT). UOT is predicted to be able to penetrate deeper into the body to measure functions and image tissues than was previously possible with other optical imaging methods.

The aim of this project is to explore the capabilities and safety of UOT regarding imaging depth and tissue property information in healthy participants, as a first step to understand the technology's capabilities and limitations.

The long-term goal, in future steps, is to develop the technology for clinical assessment of cancer-suspected lesions with a particular focus on breast cancer and for assessment of circulatory disorders in tissue.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Lund University

Malmö, Skåne County, 20502, Sweden

Location status: Recruiting

Location contact

Sophia Zackrisson, MD PhD

CONTACT

[email protected]

+46736874149

About this study

Optical tissue imaging can provide biomolecular contrast that is not readily reachable with other imaging modalities. The investigators focus on developing a technique for instantaneous measurements of blood oxygenation which have significant influence in many areas like tumour detection, myocardial infarction, or stroke. However, the technique can in addition to tissue oxygenation also in general measure the optical absorption and scattering properties of tissue, and this is what the investigators will develop and further capitalize on in this project.

In general, the spatial resolution of tissue diagnostics using optical techniques is limited to a few cm due to the strong scattering properties of tissue. Using quantum designed filter structures with large acceptance angle that are many orders of magnitude narrower than any other large acceptance angle filters, this technique can image deeper into tissue with significantly better contrast-to-noise than other optical techniques.

By analyzing the frequency shifted light only, a spatial resolution equal to the ultrasound focus can be obtained. This technique is called Ultrasound Optical Tomography (UOT). A critical factor in UOT is the ability to discriminate between the light frequency-shifted by the ultrasound and the much stronger non-frequency-shifted light.

The absorption of ultrasound in tissue increases with increasing ultrasound frequency, and therefore the ultrasound frequency preferably should be just a few MHz. The small frequency shift is why previous attempts to develop UOT techniques have had limited success: conventional filtering techniques are either not narrow enough to suppress only the carrier or has a very small acceptance angle - a serious drawback as light exiting tissue propagates in all directions.

The Quantum Information Group at the Division of Atomic Physics, Department of Physics at Lund University, has world leading experience in creating narrowband (1 MHz) filters with high (~50 dB) suppression as well as a large acceptance angle. These so-called Slow Light Filters are created in inorganic crystals doped by rare-earth ions, where laser light is used to semi-permanently transfer ions to non-absorbing states. The filters are created by "burning" a spectral hole in the absorption profile of the crystal at the frequency fS so that it transmits this frequency but absorbs the unwanted background light at the frequency fL. An added and important effect of these filters is that light propagating at the transmitted frequency, fS, will be slowed down by several orders of magnitude. In this way, any remaining background from the carrier frequency after the filter can be suppressed using time gating.

In terms of combined suppression of non-frequency shifted light and acceptance angle for the frequency shifted light, slow-light filters outperform currently existing filters by several orders of magnitude, in turn enabling orders of magnitude better contrast for tissue imaging.

In summary, UOT is an emerging technology which is predicted to reach much deeper than previous optical imaging techniques and to have an order of magnitude better signal-to noise or contras-to-noise already at 1 cm depth and 2 orders of magnitude stronger signal at 2 cm depth. It is unique in the sense of being an optical imaging technique expected to be able to utilize light transmitted through 10 cm of tissue, a feature not present in any other optical imaging technique. In this first proof-of-concept project the investigators will primarily assess the imaging depth and imaging quality in muscle and breast tissue to be able to adapt the system to better performance before moving to early clinical trials. Muscle tissue oxygenation is well studied using optical techniques and is therefore suitable for validation of UOT measurements. Breast is expected to be an excellent first clinical performance test model since the organ has a rather superficial and accessible anatomical position and offer many conventional techniques for cross-referencing. If UOT is successful in breast, it may be further developed for applications in other parts of the body and organs.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals without systemic or skin-related conditions.
  • Ability to provide informed consent.

Exclusion criteria

  • Pregnancy: Although the risk that laser illumination on the skin may affect the fetus is minimal, we will exclude pregnant research subjects for safety.
  • Skin diseases: Certain skin conditions can increase the risk of damage or complications when exposed to laser light, such as active rosacea, eczema, skin infections, or tattoos.
  • Medication: Some medications can increase the sensitivity of the skin to laser light or increase the risk of side effects. It is important to consider the person's medical history and any ongoing treatments.
  • Sunburn: Recent sun exposure of the skin may lead to increased sensitivity to laser light and can be more likely to experience discomfort or skin irritation/damage. This can both affect the reliability of the study and increase the risk of injury to the research subjects.
  • History of keloid formation or scarring: People who have a history of excessive scarring may be more likely to react with greater skin irritation from the laser light.
  • For breast measurements only: History of breast cancer or surgery. In this project, we aim to map the UOT signal only in healthy breast tissue.

Treatment and study plan

Mk1

Device

The Mk1 is an investigational device intended for UOT, a novel imaging method which can image the state of oxygenation of tissues inside the body. It is intended solely for research purposes and not for clinical diagnostic use.

The intended purpose of the Mk1 device is to serve as an investigational system to provide initial UOT measurements and images in-vivo. The performance of the system will be characterized with the aim to provide input data regarding the parameters:

  • Imaging depth
  • Contrast-to-noise ratio under relevant imaging conditions and depths
  • Correlating tissue structures seen in conventional B-scan ultrasound with structures seen in the UOT images.

Primary outcomes

  1. Depth of imaging

    Time frame: Day 1

    Maximum tissue depth where a reliable signal is achieved for both wavelengths (689 nm and 794 nm).

Secondary outcomes

  1. Signal variability

    Time frame: Day 1

    Variability in UOT signals between individuals (measured as standard deviation or coefficient of variation).

  2. Intra-individual variability (e.g., across different anatomical locations or repeated measurements).

    Time frame: Day 1

    (e.g., across different anatomical locations or repeated measurements).

  3. Normal tissue mapping

    Time frame: Day 1

    Distribution of UOT signals in arm and leg regions (mean and standard deviation for HbO2 and Hb).

  4. Breast tissue mapping:

    Time frame: Day 1

    Distribution of UOT signals in breast regions (mean and standard deviation for HbO2 and Hb).

  5. Imaging success rate

    Time frame: Day 1

    percentage of participants where all intended regions were successfully imaged

  6. Functional imaging

    Time frame: Day 1

    Quantification of oxygenation levels (HbO2, Hb) at various depths. Comparison of optical absorption values for different tissue types.

Other outcomes

  1. Frequency and severity of adverse events

    Time frame: Up until 24 hours

    e.g., skin irritation, discomfort

Study contacts

Contact information is provided by the study sponsor or research team.

Sophia Zackrisson, MD PhD

CONTACT

[email protected]

+46736874149

Sponsors and collaborators

Lead sponsor

Lund University

Other

Registry information

Official study title

Measurement and Imaging Capability of a Novel Medical Imaging Method, Ultrasound Optical Tomography, Based on Ultrasound and Laser Light in Human Tissue

Acronym: DOIT

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.